Catechol O-methyltransferase

Catechol O-methyltransferase (COMT) is a key enzyme in the regulation of melatonin synthesis, which is involved in the regulation of plant growth and development, and can be inhibited by structurally specific heparin oligosaccharides.

Serotonin hydrochloride (Serotonin HCl) is an endogenous 5-HT receptor agonist, a monoamine neurotransmitter in the CNS, and a catechol O-methyltransferase (COMT) inhibitor(Ki=44 μM).

Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor with an IC50 of 151 nM. Entacapone is also a potential obesity-related gene (FTO) inhibitor that can inhibit FTO demethylation activity and be used in the study of metabolic diseases.

Entacapone sodium salt inhibits catechol-O-methyltransferase(COMT) with similar IC50 in different tissues including live, duodenum, kidney and lung, but entacapone is more active than tolcapone in those tissues. Entacapone (< 100 μM) is a potent inhibitor of α-syn and β-amyloid (Aβ) oligomerization and fibrillogenesis, and also protects against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.Entacapone sodium salt is a specific, potent, peripherally acting catechol-O-methyltransferase (COMT) inhibitor with IC50 of 151 nM for PD treatment.

Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor and is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of CO

Opicapone (BIA 9-1067) reduces the ATP content of the cells (IC50: 98 μM). Opicapone is an effective third-generation catechol-O-methyltransferase inhibitor for the research of Parkinson's disease and motor fluctuations.

DHNPA, a novel catechol-O-methyltransferase (COMT) inhibitor, demonstrates its significance in the field of chemistry.

Serotonin hydrogen maleate serves as a monoaminergic neurotransmitter and an endogenous 5-HT receptor agonist within the central nervous system (CNS). It also functions as an inhibitor of catechol O-methyltransferase (COMT), exhibiting a Ki value of 44 μM.

Entacapone acid (AG 1290) is a selective and reversible inhibitor of catechol-O-methyltransferase(COMT).

BIA 3-335, an inhibition of catechol-O-methyltransferase, could have applications for Parkinson's Disease.

CGP-28014 is an inhibitor of catechol-O-methyltransferase. CGP-28014 increases the renal excretion of both dopamine and dihydroxyphenylacetic acid (DOPAC) but does not affect renal sodium handling indicating a different mechanism of action. CGP-28014 sign

DHMPA is an inhibitor of catechol-O-methyltransferase (COMT), it also reduces tissue norepinephrine and blood pressure.

Ro 61-1448 is a metabolite of tolcapone, a catechol-O-methyltransferase inhibitor.

U-0521, an inhibitor of catechol-O-methyltransferase (COMT), enhances the availability and utilization of levodopa in the brain.

3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

Methylspinazarin is a naphthoquinone bacterial metabolite that has been found in Streptomyces and is an inhibitor of catechol O-methyltransferase (COMT; IC50 = 0.8 μg/ml).1 It is selective for COMT over tyrosine hydroxylase, DOPA decarboxylase, and dopamine-β-hydroxylase at 100 μg/ml. Methylspinazarin decreases blood pressure in spontaneously hypertensive rats when administered at a dose of 50 mg/kg. |1. Chimura, H., Sawa, T., Takita, T., et al. Methylspinazarin and dihydromethylspinazarin, gatechol-O-methyl transerfase inhibitors produced by Streptomyces. J. Antibiot. 26(2), 112-114 (1973).

Tolcapone (Ro 40-7592) is a catechol-O-methyltransferase inhibitor employed as an adjunctive therapy with levodopa and carbidopa in the treatment of Parkinson's disease.

cis-Entacapone is a metabolite of the catechol-O-methyltransferase (COMT) inhibitor entacapone. It is also a potential impurity found in commercial preparations of entacapone and a degradant of entacapone formed by UV light exposure.

COMT-IN-1 (compound C12) is a nitrophenol analog and an orally active catechol-O-methyltransferase (COMT) inhibitor. It exhibits IC50 values of 0.37 μM for COMT, 95.58 μM for MAO-A, and 58.82 μM for MAO-B, demonstrating its inhibitory activity on these enzymes. Additionally, COMT-IN-1 displays chelation properties with various metal ions and has good blood-brain barrier permeability. This compound enhances dopamine levels in mice and ameliorates symptoms of MPTP-induced Parkinsons disease (PD).

3-Methoxy-L-tyrosine-d3 monohydrate is a deuterated compound of 3-Methoxy-L-tyrosine monohydrate. 3-Methoxy-L-tyrosine monohydrate has a CAS number of 200630-46-2. 3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

Entacapone (Standard) is a reference standard for research and analysis in studies involving Entacapone. Entacapone is a potent and specific peripheral catechol-O-methyltransferase (COMT) inhibitor with an IC50 of 151 nM. Entacapone is also a potential obesity-related gene (FTO) inhibitor that can inhibit FTO demethylation activity and be used in the study of metabolic diseases.

3',8-Dihydroxy-4',6,7-trimethoxyisoflavone is a catechol-O-methyltransferase inhibitor with an IC50 of 0.2 g/mL.